협심증 치료제 시장 : 세계 예측(2026-2032년)

The Angina Pectoris Medication Market is projected to grow by USD 7.09 billion at a CAGR of 10.21% by 2032.

Angina Pectoris Medication: Executive Summary

Angina pectoris medication encompasses therapies used to prevent or relieve myocardial ischemic symptoms and to reduce cardiovascular risk. Treatment decisions depend on angina type, symptom burden, comorbidities, contraindications, adherence, and access to diagnostic and follow-up services. The clinical foundation generally combines symptom-directed antianginal therapy with secondary prevention, including antiplatelet treatment, lipid management, blood-pressure control, smoking cessation, and lifestyle intervention when appropriate.

Treatment Is Shifting Toward Risk-Based, Integrated Care

The treatment landscape is moving from episodic symptom relief toward integrated management of ischemic risk and the underlying cardiovascular profile. Greater emphasis is being placed on guideline-directed therapy, medication reconciliation, adherence support, and earlier evaluation of persistent or atypical symptoms. Digital prescribing, remote monitoring, pharmacogenomic research, and expanded use of noninvasive assessment are also influencing care pathways, while affordability, polypharmacy, adverse effects, and uneven access remain practical barriers.

Artificial Intelligence Supports Triage, Safety, and Personalization

Artificial intelligence is being applied to electrocardiogram interpretation, clinical decision support, risk stratification, medication-safety checks, and identification of patients who may benefit from further evaluation. In angina care, its most immediate value is likely to come from combining structured clinical data with imaging, laboratory results, and longitudinal adherence information. Safe deployment requires representative validation, explainable outputs, clinician oversight, protection of health information, and monitoring for false reassurance or inappropriate treatment escalation.

Regional Insights: Access and Care Models Shape Medication Use

North America generally combines broad access to advanced diagnostics with substantial cost and adherence challenges. Europe emphasizes guideline-based cardiovascular prevention, although reimbursement and delivery models vary across countries. Asia-Pacific includes highly developed systems alongside rapidly expanding access, creating wide differences in diagnosis and continuity of care. Latin America continues to face disparities in specialist access, medicine affordability, and preventive care. The Middle East is investing in cardiovascular services but experiences differences between well-resourced urban systems and underserved populations. Africa faces major gaps in screening, essential medicine availability, and specialist capacity, making primary-care integration especially important.

Group Insights: Economic and Institutional Differences Drive Variation

ASEAN markets reflect considerable diversity in insurance coverage, health infrastructure, urbanization, and access to cardiology services. BRICS members span large and varied populations, with cardiovascular prevention shaped by national formularies, public procurement, and regional disparities. The European Union benefits from shared clinical and regulatory frameworks but retains differences in reimbursement and implementation. G7 systems generally have mature clinical infrastructures while confronting aging populations, multimorbidity, and sustainability pressures. GCC countries are expanding specialized and digital care, with prevention and workforce development remaining priorities. NATO members include diverse health systems, so medication access and continuity depend on national policy rather than alliance membership alone.

Country Insights: National Guidelines and Access Determine Treatment Pathways

Australia and Canada combine established cardiovascular services with geographic access challenges. Brazil, Mexico, India, China, and Russia must address substantial regional variation in diagnosis, affordability, and continuity of treatment. France, Germany, Italy, Spain, and the United Kingdom operate within mature European care environments, but differ in reimbursement, prescribing practice, and waiting times. Japan and South Korea have advanced health systems with strong preventive-care capabilities, alongside aging-related demand and polypharmacy considerations. The United States offers extensive therapeutic and diagnostic options, while out-of-pocket costs, insurance variation, and care fragmentation can affect adherence.

Actions for Leaders: Improve Adherence, Equity, and Clinical Evidence

Industry leaders should prioritize evidence-based therapies that address both symptoms and cardiovascular risk, while supporting appropriate combination use and medication review. Patient-centered adherence programs should be designed around affordability, dosing simplicity, side-effect education, and culturally appropriate communication. Partnerships with health systems can strengthen primary-care screening, referral pathways, and post-prescription follow-up. Artificial intelligence initiatives should begin with narrowly defined clinical needs, prospective validation, bias assessment, and clear accountability. Access strategies should align with national formularies, public procurement, and underserved-community requirements rather than relying on a uniform global model.

Methodology: Evidence-Based Synthesis of Clinical and Health-System Factors

This executive summary synthesizes established clinical principles, public health guidance, peer-reviewed evidence, and documented health-system characteristics relevant to angina pectoris medication. Analysis is organized by treatment evolution, artificial-intelligence applications, geography, economic and institutional groupings, and country-level care conditions. Claims are framed qualitatively to avoid unsupported numerical estimates, market sizing, market shares, or forecasts. Regional and country comparisons reflect differences in access, regulation, prevention, infrastructure, and care delivery rather than assumptions about individual patients.

Conclusion: Effective Angina Care Depends on Integrated, Equitable Delivery

Angina pectoris medication is most effective when symptom control is integrated with secondary prevention, accurate diagnosis, regular review, and support for sustained adherence. Regional and national differences in affordability, infrastructure, and clinical capacity will continue to shape outcomes. Leaders can create the greatest value by combining rigorously evaluated therapies with accessible care pathways, responsible artificial intelligence, and targeted efforts to reduce disparities in cardiovascular prevention and treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Angina Pectoris Medication Market, by Drug Type

• 7.1. Introduction
• 7.2. Ace Inhibitors
• 7.3. Antiplatelets
• 7.4. Beta Blockers
  • 7.4.1. Cardio Selective
  • 7.4.2. Non Selective
• 7.5. Calcium Channel Blockers
  • 7.5.1. Dihydropyridines
  • 7.5.2. Non Dihydropyridines
• 7.6. Nitrates
  • 7.6.1. Long Acting
  • 7.6.2. Short Acting

8. Angina Pectoris Medication Market, by Dosage Form

• 8.1. Introduction
• 8.2. Capsule
• 8.3. Injection
• 8.4. Patch
• 8.5. Solution
• 8.6. Tablet

9. Angina Pectoris Medication Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Intravenous
• 9.3. Oral
• 9.4. Sublingual
• 9.5. Transdermal

10. Angina Pectoris Medication Market, by Condition Type

• 10.1. Introduction
• 10.2. Microvascular Angina
• 10.3. Stable Angina
• 10.4. Unstable Angina
• 10.5. Vasospastic Angina

11. Angina Pectoris Medication Market, by Patient Age Group

• 11.1. Introduction
• 11.2. Adult
• 11.3. Geriatric
• 11.4. Pediatric

12. Angina Pectoris Medication Market, by Release Profile

• 12.1. Introduction
• 12.2. Immediate Release
• 12.3. Sustained Release

13. Angina Pectoris Medication Market, by Packaging Format

• 13.1. Introduction
• 13.2. Blister Pack
• 13.3. Bottle
• 13.4. Pre Filled Syringe
• 13.5. Tube

14. Angina Pectoris Medication Market, by Distribution Channel

• 14.1. Introduction
• 14.2. Hospital Pharmacy
  • 14.2.1. Private Hospital Pharmacy
  • 14.2.2. Public Hospital Pharmacy
• 14.3. Online Pharmacy
  • 14.3.1. Otc Online Pharmacy
  • 14.3.2. Prescription Online Pharmacy
• 14.4. Retail Pharmacy
  • 14.4.1. Chain Pharmacy
  • 14.4.2. Independent Pharmacy

15. Angina Pectoris Medication Market, by End User

• 15.1. Introduction
• 15.2. Clinics
• 15.3. Homecare
• 15.4. Hospitals

16. Angina Pectoris Medication Market, by Region

• 16.1. Introduction
• 16.2. Asia-Pacific
• 16.3. North America
• 16.4. Latin America
• 16.5. Europe
• 16.6. Middle East
• 16.7. Africa

17. Angina Pectoris Medication Market, by Group

• 17.1. Introduction
• 17.2. ASEAN
• 17.3. GCC
• 17.4. European Union
• 17.5. BRICS
• 17.6. G7
• 17.7. NATO

18. Angina Pectoris Medication Market, by Country

• 18.1. Introduction
• 18.2. United States
• 18.3. Canada
• 18.4. Mexico
• 18.5. Brazil
• 18.6. United Kingdom
• 18.7. Germany
• 18.8. France
• 18.9. Russia
• 18.10. Italy
• 18.11. Spain
• 18.12. China
• 18.13. India
• 18.14. Japan
• 18.15. Australia
• 18.16. South Korea

19. Competitive Landscape

• 19.1. Market Share Analysis, 2025
• 19.2. Market Concentration Analysis, 2025
  • 19.2.1. Concentration Ratio (CR)
  • 19.2.2. Herfindahl Hirschman Index (HHI)
• 19.3. Recent Developments & Impact Analysis, 2025
• 19.4. Product Portfolio Analysis, 2025
• 19.5. Benchmarking Analysis, 2025

20. Company Profiles

• 20.1. Abbott Laboratories
• 20.2. Amgen Inc.
• 20.3. AstraZeneca PLC
• 20.4. Bayer AG
• 20.5. Boehringer Ingelheim International GmbH
• 20.6. Bristol-Myers Squibb Company
• 20.7. Eli Lilly and Company
• 20.8. Gilead Sciences, Inc.
• 20.9. GlaxoSmithKline plc (GSK)
• 20.10. Johnson & Johnson
• 20.11. Merck & Co., Inc.
• 20.12. Novartis AG
• 20.13. Otsuka Pharmaceutical Co., Ltd.
• 20.14. Pfizer Inc.
• 20.15. Sanofi S.A.
• 20.16. Sun Pharmaceutical Industries Ltd.
• 20.17. Teva Pharmaceutical Industries Ltd.

21. Key Experts